Sara Rosenbaum, JD, the Harold and Jane Hirsh Professor of Health Law and Policy and founding chair of the Department of Health Policy at the Milken Institute School of Public Health, George Washington University, discusses the potential impact the Trump administration will have on Medicaid programs.
Sara Rosenbaum, JD, the Harold and Jane Hirsh Professor of Health Law and Policy and founding chair of the Department of Health Policy at the Milken Institute School of Public Health, George Washington University, discusses the potential impact the Trump administration will have on Medicaid programs.
Transcript
What impact do you think the Trump administration’s willingness to provide waivers to states for their Medicaid programs could have on healthcare outcomes?
I think that the discussion that we are having now about how to make public health care financing better and stronger. This is a discussion that has been going on for as long as we’ve had public health insurance programs. We are now in the sixth decade of that. I don’t think that the administration initiative as they are framed now are being advanced to continue a long discussion about how to improve the performance of these programs. I think the administration made clear from the first day it took office that the Medicaid program originally was not intended to insure low-income people who were not connected to cash welfare. Nonetheless, it has evolved into that.
Now, it’s our public insurance program and the question is how to make it work better, how to create new options for using alternative approaches to public insurance that would look and feel maybe more like Medicare advance plans where Medicare buys from the private sector which we already do this in Medicaid. Expand the options, look for areas of efficiency in long term service and support. And I should note it’s about how we can support people who are poor and depend on Medicaid who need work supports and a job. But it’s not about creating circumstances where people are made to feel they are liable to lose something for no reason of their own. I don’t see that as the way to go. I also think that the discussion we need to have is around how to build support for work into Medicaid expansions not how to use the work demonstrations to roll back benefits.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More